Article

Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study

Department of Epidemiology, Institute of Public Health, Aarhus University, Bartolin Allé 2, DK-8000 Aarhus, Denmark.
BMJ (online) (Impact Factor: 16.38). 09/2009; 339:b3569. DOI: 10.1136/bmj.b3569
Source: PubMed

ABSTRACT To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations.
Population based cohort study.
493 113 children born in Denmark, 1996-2003.
Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005.
Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low-for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI.
There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI.

Download full-text

Full-text

Available from: Tine Brink Henriksen, Aug 01, 2015
0 Followers
 · 
144 Views
  • Source
    • "Revue de la littérature paroxétine d'avoir un enfant avec une anomalie cardiaque est de presque 2 % alors que ce même risque dans la population générale est estimé à 1 %. Une autre étude [6] est arrivée aux mêmes conclusions avec la sertraline et le citalopram, et ce surtout en cas d'association de deux IRS. D'autres revues de la littérature et méta-analyses ont conclu que la fréquence des anomalies congénitales chez les enfants des femmes sous IRS pendant le premier trimestre de la grossesse est susceptible d'être augmentée de façon faible, voire pas du tout [7] [8] [9] [10] [11] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract in French and in English Résumé La grossesse et le postpartum sont des périodes particulières concernant l’utilisation de psychotropes chez la future mère. La prescription thérapeutique doit tenir compte du risque éventuel de malformation chez le fœtus, de syndrome de sevrage chez le nouveau-né, du type d’allaitement et du risque potentiel de la maladie mentale maternelle non traitée. Les recommandations de bonne pratique sont en perpétuel remaniement et leurs conclusions parfois contradictoires. Méthode : le but de ce travail est d’élaborer un référentiel actualisé à partir d’une revue de la littérature, facile d’utilisation pour tout professionnel concerné par le suivi ou la prescription d’un traitement psychotrope (antidépresseurs, anxiolytiques-hypnotiques, neuroleptiques, thymorégulateurs et traitements de substitution de la dépendance aux opiacés) chez une femme enceinte ou qui allaite. Résultats : ces mises au point, sous forme de tableaux, se basent également sur notre expérience clinique en tant qu’équipe spécialisée en médecine périnatale. Summary Pregnancy and the postpartum periods are particular for the mother's use of drugs. Therapeutic prescription must take into account the potential risk of fetal malformation, newborn's withdrawal syndrome, feeding type and potential risk of untreated maternal mental illness. Recommendations for good practice are constantly remodeling and their conclusions are sometimes contradictory. Method: The aim of this work is to develop an updated review, easy to use for any professional involved in the monitoring or prescription of a psychotropic medication (antidepressants, anxiolytics-hypnotics, neuroleptics, mood stabilizers and substitution treatment of opioid dependance) for pregnant or nursing women. Results: These updates in tabular form are also based on our clinical experience as a team specializing in perinatal medicine.
    La Presse Médicale 01/2015; 44(3):271-283. DOI:10.1016/j.lpm.2014.07.026 · 1.17 Impact Factor
  • Source
    • "This dataset reported an exposed sample size of 2631 (mean per sample 374±288) and control sample size of 497,307 (mean per sample 71,058±65,143). No unpublished data was collected and two papers (Wen et al., 2006; Pedersen et al., 2009) reporting SSRI exposure not differentiated by agent were included as independent samples. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Context:It has been suggested that the commonly prescribed class of antidepressants selective serotonin reuptake inhibitors (SSRIs) are associated with birth defects. However, the teratogenic effect of individual SSRIs has not been previously compared using meta-analysis.Objective:To determine the strength of the association between individual SSRIs and major, minor, and cardiac malformation among infants born to women taking these medications.Data sources:Electronic search of CINAHL, EMBASE, Medline, PsycINFO, and ISI Web of Science using the search terms (SSRI OR antidepressant) AND (obstetric outcome OR malformation OR birth outcome OR teratogen), supplemented by manual searching of published references and requests of primary researchers for unpublished data.Study selection:There were 115 studies identified by electronic search and reviewed in full text, which yielded 16 papers reporting 36 data samples for major malformations, nine papers reporting 26 data samples for cardiac malformations, and four papers reporting seven data samples for minor malformations.Data synthesis:Fluoxetine (OR 1.14, 95% CI 1.01-1.30) and paroxetine (OR 1.29, 95% CI 1.11-1.49) were associated with increased risk of major malformations. Paroxetine was associated with increased risk of cardiac malformations (OR 1.44, 95% CI 1.12-1.86). Sertraline and citalopram were not significantly associated with congenital malformation. Between-sample heterogeneity was low and a range of methodological considerations had no significant impact on effect size. There was little evidence of publication bias.Conclusions:Fluoxetine and paroxetine should be avoided in the first trimester and among those at risk of an unplanned pregnancy.
    Australian and New Zealand Journal of Psychiatry 06/2013; 47(11). DOI:10.1177/0004867413492219 · 3.77 Impact Factor
  • Source
    • "are reminiscent of the congenital cardiac defects seen with intrauterine SSRI exposure in humans [31] [32] [33] [34]. However, the third trimester of human neurodevelopment is best modeled in neonatal mice and rats. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Selective serotonin reuptake inhibitor (SSRI) therapy complicates up to 10% of pregnancies. During therapy, SSRIs exert pleiotropic antidepressant, anorexigenic, and neurotrophic effects. Intrauterine SSRI exposure has been modeled by neonatal administration to developmentally immature rodents, and it has paradoxically elicited features of adult depression. We hypothesized neonatal SSRI exposure likewise programs a rebound hypermetabolic state in adult mice. Methods. C57BL/6 pups were randomized to saline or sertraline (5 mg/kg/d) from P1-P14. Because estrogen increases tryptophan hydroxylase 2 (TPH2) expression, a subset of female mice underwent sham surgery or bilateral ovariectomy (OVX). Metabolic rate was determined by indirect calorimetry. Results. In both male and female mice, neonatal SSRI exposure increased adult caloric intake and metabolic rate. SSRI-exposed female mice had significantly decreased adult weight with a relative increase in brain weight and melatonin excretion, independent of ovarian status. Cerebral cortex TPH2 expression was increased in SSRI-exposed male mice but decreased in OVX SSRI-exposed female mice. Conclusions. SSRI exposure during a critical neurodevelopmental window increases adult caloric intake and metabolic rate. Ovarian status modulated central TPH2 expression, but not adult energy balance, suggesting programmed neural connectivity or enhanced melatonin production may play a more important role in the post-SSRI hypermetabolic syndrome.
    Journal of nutrition and metabolism 04/2012; 2012:431574. DOI:10.1155/2012/431574
Show more